Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Articolo
Data di Pubblicazione:
2025
Citazione:
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) / Sharman, J.P., Munir, T., Grosicki, S., Roeker, L.E., Burke, J.M., Chen, C.I., Grzasko, N., Follows, G., Matrai, Z., Sanna, A., Qiu, L., Feng, R., Hua, V.M., Jurczak, W., Ritgen, M., Yi, S., Bosch, F., Coombs, C.C., Bao, K., Patel, V., et al.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 1527-7755. - 43:23(2025), p. 2658. [10.1200/JCO-25-01356]
Tipologia CRIS:
1.1.5. Erratum
Elenco autori:
Sharman, J. P.; Munir, T.; Grosicki, S.; Roeker, L. E.; Burke, J. M.; Chen, C. I.; Grzasko, N.; Follows, G.; Matrai, Z.; Sanna, A.; Qiu, L.; Feng, R.; Hua, V. M.; Jurczak, W.; Ritgen, M.; Yi, S.; Bosch, F.; Coombs, C. C.; Bao, K.; Patel, V.; Liu, B.; Compte, L.; Guntur, A.; Wang, D. Y.; Hill, M.; Leow, C. C.; Ghia, P.; Barr, P. M.
Link alla scheda completa:
Pubblicato in: